RenovoRx (NASDAQ:RNXT) Stock: Insider Ramtin Agah Acquires 50,000 Shares

RenovoRx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CMO Ramtin Agah bought 50,000 RenovoRx shares at an average price of $0.93, investing $46,500 and increasing his holdings by 6.26% to 848,460 shares.
  • RenovoRx shares fell 8.2%; the stock opened at $0.95, below its 50-day moving average of $1.42.
  • The latest quarter showed an EPS loss of $0.07, missing estimates by $0.01, while revenue of $1.07 million slightly exceeded forecasts. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $8.50.
  • Five stocks to consider instead of RenovoRx.

RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) CMO Ramtin Agah acquired 50,000 shares of the company's stock in a transaction on Monday, November 16th. The shares were acquired at an average cost of $0.93 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the chief marketing officer owned 848,460 shares of the company's stock, valued at approximately $789,067.80. The trade was a 6.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

RenovoRx Trading Down 8.2%

RNXT opened at $0.95 on Tuesday. The firm has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.11. RenovoRx, Inc. has a twelve month low of $0.73 and a twelve month high of $2.59.

RenovoRx (NASDAQ:RNXT - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative net margin of 469.02% and a negative return on equity of 133.49%. The business had revenue of $1.07 million for the quarter, compared to analysts' expectations of $1.06 million. Equities research analysts anticipate that RenovoRx, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on RNXT shares. Weiss Ratings upgraded RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 2nd. Wall Street Zen downgraded RenovoRx from a "hold" rating to a "sell" rating in a research note on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, RenovoRx presently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Get Our Latest Stock Analysis on RNXT

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in RenovoRx by 501.6% during the third quarter. State Street Corp now owns 314,636 shares of the company's stock valued at $491,000 after buying an additional 262,332 shares during the period. T3 Companies LLC bought a new position in shares of RenovoRx in the third quarter worth approximately $151,000. Finally, Cetera Investment Advisers raised its stake in RenovoRx by 205.1% in the third quarter. Cetera Investment Advisers now owns 57,976 shares of the company's stock valued at $90,000 after purchasing an additional 38,976 shares in the last quarter. 3.10% of the stock is currently owned by hedge funds and other institutional investors.

About RenovoRx

(Get Free Report)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company's platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

Featured Articles

Insider Buying and Selling by Quarter for RenovoRx (NASDAQ:RNXT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in RenovoRx Right Now?

Before you consider RenovoRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RenovoRx wasn't on the list.

While RenovoRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines